PHIBRO ANIMAL HEALTH CORP

Phibro Animal Health Corporation (Nasdaq: PAHC) is a leading global diversified animal health and mineral nutrition company that develops, manufactures, and markets products to improve the health and productivity of livestock and companion animals. The company operates through three reportable segments: Animal Health, which generates 77 percent of revenue; Mineral Nutrition, representing 19 percent of revenue; and Performance Products, accounting for 5 percent of revenue.

The Animal Health segment encompasses approximately 345 product lines including medicated feed additives, anticoccidials, nutritional specialty products, vaccines, and vaccine adjuvants. Core brands include Stafac, Terramycin, Mecadox, Nicarb, Aviax, and OmniGen. In October 2024, Phibro completed the acquisition of Zoetis's medicated feed additive portfolio, water-soluble products, and related assets, which expanded the company's product offerings to include brands such as Aureomycin, LincoSpectin, BMD, Avatec, Bovatec, and Cygro. The Mineral Nutrition segment manufactures approximately 380 formulations of trace minerals including zinc, manganese, copper, and iron, marketed under brands like GemStone and Vistore. The Performance Products segment manufactures specialty ingredients for personal care, industrial chemical, and chemical catalyst industries.

Phibro markets approximately 790 product lines across approximately 90 countries to approximately 4,800 customers. The company's geographic footprint spans North America, Latin America, Europe, Middle East, Africa, and Asia Pacific, with the United States representing 58 percent of total revenue. By species, poultry accounts for 36 percent of sales, followed by cattle at 18 percent, dairy at 15 percent, and swine at 11 percent.

The company maintains approximately 1,465 animal health product registrations globally and holds or has exclusive rights to approximately 290 patents or pending applications across more than 40 countries. Phibro operates manufacturing facilities across multiple continents, including six sites acquired from Zoetis comprising four locations in the United States, one in Italy, and one in China. The company's competitive advantages include proprietary formulations, trade secret manufacturing techniques, established distribution networks, and a portfolio of recognized trademarks built over decades of commercial operation.